{"id":23389,"date":"2023-07-19T13:53:18","date_gmt":"2023-07-19T11:53:18","guid":{"rendered":"https:\/\/www.izb-online.de\/leon-nanodrugs-begruesst-dr-hans-frickel-als-neuen-ceo-innovations-und-gruenderzentrum-biotechnologie-izb\/"},"modified":"2023-07-27T10:00:23","modified_gmt":"2023-07-27T08:00:23","slug":"leon-nanodrugs-welcomes-dr-hans-frickel-as-new-chief-executive-officer-innovations-und-gruenderzentrum-biotechnologie-izb","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/leon-nanodrugs-welcomes-dr-hans-frickel-as-new-chief-executive-officer-innovations-und-gruenderzentrum-biotechnologie-izb\/","title":{"rendered":"leon-nanodrugs welcomes Dr. Hans Frickel as new CEO"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

leon-nanodrugs welcomes Dr. Hans Frickel as new CEO<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]Dr. Frickel has more than 20 years of experience in strategic and operational leadership roles in the pharmaceutical and medical device industries.[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]July, 2023[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns” el_id=”corona-ausblenden”][vc_column_inner el_class=”bild-zwei-spalten-links”][vc_single_image image=”6283″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Pieris[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]The Lungs[\/vc_column_text][vc_single_image image=”6285″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Pieris[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Stephen S. Yoder<\/strong>, CEO, Pieris Pharmaceuticals Inc.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”23387″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 leon-nanodrugs[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Hans Frickel, CEO of LEON[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\u201cI am excited to join LEON as we work to transform nanomedicine manufacturing.\u201d<\/h6>\n

Dr. Hans Frickel, CEO of LEON<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]leon-nanodrugs GmbH (\u201cLEON\u201d), an IZB-based pharmatec company, announced the appointment of Dr. Hans Frickel as CEO, effective July 1, 2023. Dr. Hans Frickel, a trained pharmacist and industrial manager, brings more than 20 years of experience in strategic and operational leadership roles across the entire value chain of pharmaceuticals and medical devices. Prior to joining LEON, he served as Managing Director at R-Biopharm and held several senior operational management roles at BioNTech, Evonik, Midas Pharma, Procter & Gamble and Merck.<\/p>\n

Dr. Hubert Birner, Chairman of the LEON Supervisory Board, said: \u201cOn behalf of the Supervisory Board, I am delighted to welcome Dr. Hans Frickel to LEON. With his extensive expertise in different areas of modern drug manufacturing, including plant management and QC, as well as a strong track record in strategy and governance, he is an ideal fit to take LEON to the next stage. On behalf of the Supervisory Board I also would like to thank our interim CEO and CFO Christian Nafe, our CSO Dr. Setu Kasera and their team for their tremendous work in driving our technology towards commercialization and for the great progress that has been achieved to date.\u201d<\/p>\n

\u201cI am excited to join LEON as we work to transform nanomedicine manufacturing,\u201d said Dr. Hans Frickel, CEO of LEON. \u201cI am impressed with the team\u2019s knowledge and dedication in working to create added value across the nano formulation processing chain. I truly believe that LEON\u2019s NANO devices will significantly improve development and manufacturing for current and future standardized and personalized cell & gene therapies at CDMOs, biotech and pharma companies.\u201d<\/p>\n

leon-nanodrugs (\u201cLEON\u201d) specialises in the development and marketing of devices for the encapsulation of genetic material and other active substances into nanodrug carriers, such as lipid nanoparticles (LNPs).
\n<\/strong>leon-nanodrugs GmbH (\u201cLEON\u201d) is a pharmatech company specializing in the development and marketing of devices for the encapsulation of genetic material and other active substances into nanodrug carriers, such as lipid nanoparticles (LNPs). The Munich-based private company builds its innovative solutions based on its proprietary FR-JET Technology, enabling pharma companies and small biotechs as well as CDMOs to optimize nanomedicine manufacturing and take full advantage of the significant progress being made in advanced therapies. LEON’s GMP-compliant, aseptic devices NANOme and NANOus increase efficiency in the production of nano drug carriers and are suitable for both clinical-scale and commercial production. In addition to its product offering, LEON will provide in-house lab capacity for process development with its own devices. For further information, please visit leon-nanodrugs.com<\/a> and follow LEON on LinkedIn<\/a> and Twitter<\/a>.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n